Correct Answer: B. Elastase
α1-antitrypsin (AAT) is a serine protease inhibitor (serpin) synthesized primarily in the liver. Its cardinal role is to inhibit elastase, a neutrophil-derived serine protease released during inflammation. Elastase degrades elastin in the extracellular matrix, particularly in lung tissue. The balance between elastase activity and AAT inhibition is critical: when AAT is deficient (genetic mutations in the SERPINA1 gene), unopposed elastase activity causes progressive elastic fiber destruction, leading to early-onset emphysema, especially in smokers. This is the pathophysiological basis of α1-antitrypsin deficiency disease. AAT also inhibits other proteases (cathepsin G, proteinase 3), but elastase is its primary and most clinically significant target. In Indian populations, while AAT deficiency is less common than in Caucasians, it remains an important differential diagnosis in young patients with emphysema or chronic obstructive pulmonary disease (COPD) without significant smoking history. The protease-antiprotease imbalance theory explains why AAT replacement therapy is used in severe deficiency states.
Why the other options are wrong
A. Collagenase — Collagenase (matrix metalloproteinase-1) is inhibited by tissue inhibitors of metalloproteinases (TIMPs), not by α1-antitrypsin. AAT is a serpin that targets serine proteases, not metalloproteinases. This option exploits confusion between different protease inhibitor families. C. Catalase — Catalase is an antioxidant enzyme that breaks down hydrogen peroxide; it is not inhibited by AAT. This is a distractor that confuses enzyme classification—catalase is not a protease and has no mechanistic relationship with α1-antitrypsin inhibition. D. Phospholipase — Phospholipase is a hydrolytic enzyme involved in lipid metabolism and is not a target of α1-antitrypsin. AAT specifically inhibits serine proteases; phospholipase belongs to a different enzyme class and is regulated by different inhibitor systems.
High-Yield Facts
- α1-antitrypsin is a serpin (serine protease inhibitor) synthesized by the liver; its primary target is neutrophil elastase.
- Protease-antiprotease imbalance: unopposed elastase in AAT deficiency causes elastic fiber degradation → early emphysema (age <45 years, basilar predominance).
- SERPINA1 gene mutations (PiZZ genotype most severe) cause AAT deficiency; heterozygotes (PiMZ) have intermediate risk.
- AAT level <57 μmol/L (11 mg/dL) is considered deficient and warrants genetic testing and counseling in India.
- Smoking accelerates lung disease in AAT deficiency by 15–20 years compared to non-smokers; synergistic oxidative stress.
- AAT also inhibits cathepsin G and proteinase 3, but elastase inhibition is the clinically dominant mechanism in lung pathology.
Mnemonics
AAT → ELASTASE (Lung Destruction) Alpha-1 Antitrypsin inhibits Elastase → Emphysema when deficient. Remember: AAT protects Elastic fibers in lungs from Elastase damage. Serpin vs. Metalloproteinase Inhibitors Serpins (AAT, C1-inhibitor) block serine proteases (elastase, thrombin). TIMPs block metalloproteinases (collagenase, gelatinase). Different families, different targets.
NBE Trap
NBE pairs "antitrypsin" with "protease" to lure students into selecting collagenase or phospholipase—enzymes that sound like proteases but are not serine proteases and are not inhibited by AAT. The trap exploits incomplete understanding of protease classification.
Clinical Pearl
In Indian clinical practice, young patients (age <40 years) presenting with emphysema or recurrent respiratory infections without significant smoking history should raise suspicion for AAT deficiency. Serum AAT level and PiMZ/PiZZ genotyping are cost-effective screening tools; early diagnosis enables counseling on smoking avoidance and consideration for augmentation therapy in severe cases.
_Reference: Robbins and Cotran Pathologic Basis of Disease, Ch. 15 (Genetic Disorders); Harrison's Principles of Internal Medicine, Ch. 181 (Chronic Obstructive Pulmonary Disease)_